The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 33.56% and 13.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...